Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
abbvie
6
×
biotech
boston blog main
boulder/denver blog main
boulder/denver top stories
cancer immunotherapy
6
×
detroit blog main
6
×
detroit top stories
indiana blog main
indiana top stories
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
boston top stories
clinical trials
startups
biogen
cancer
deals
fda
gilead sciences
nonalcoholic steatohepatitis
novartis
alzheimer's disease
astrazeneca
What
bio
6
×
roundup
6
×
drug
acquisitions
ceo
companies
nash
news
abbvie’s
ahead
albert
alzheimer’s
announced
annual
approval
approved
assessed
attention
biggest
biofourmis
biogen’s
biopharmaceutical
biotech
bourla
bucks
cancer
celebrate
chance
collabs
communities
company
conference
convo
corner
covid
crispr
daniel
day
days
deal
Language
unset
unknown
Current search:
roundup
×
bio
×
" detroit blog main "
×
" cancer immunotherapy "
×
abbvie
×
@xconomy.com
3 years ago
Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More